Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeligekimab in Non-Radiographic Axial Spondyloarthritis
NCT07339566Phase 3Not yet recruiting
- Sponsor
- Lingli Dong
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of xeligekimab in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Lingli Dong. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
xeligekimab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT07339566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339566.